The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
X Demographics
Mendeley readers
Attention Score in Context
Title |
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
|
---|---|
Published in |
Molecular Cancer Therapeutics, September 2018
|
DOI | 10.1158/1535-7163.mct-17-1148 |
Pubmed ID | |
Authors |
Kathryn M Lemberg, James J Vornov, Rana Rais, Barbara S Slusher |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 14% |
Unknown | 6 | 86% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 86% |
Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 110 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 20% |
Student > Ph. D. Student | 17 | 15% |
Student > Bachelor | 5 | 5% |
Student > Doctoral Student | 5 | 5% |
Other | 4 | 4% |
Other | 13 | 12% |
Unknown | 44 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 22 | 20% |
Chemistry | 11 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Immunology and Microbiology | 5 | 5% |
Medicine and Dentistry | 4 | 4% |
Other | 11 | 10% |
Unknown | 52 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2024.
All research outputs
#3,295,193
of 26,473,472 outputs
Outputs from Molecular Cancer Therapeutics
#469
of 4,148 outputs
Outputs of similar age
#61,217
of 349,373 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#4
of 52 outputs
Altmetric has tracked 26,473,472 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,148 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,373 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.